Xgeva Market Report 2026

Xgeva Market Overview

• The Xgeva market growth in the historic period has been driven by improved understanding of bone metastasis management, advancement in rnk ligand inhibition research • Market expansion is supported by increasing prevalence of metastatic cancers, rising demand for osteoporosis and bone health treatments • Growth Driver: Increasing Prevalence Of Bone Metastasis Boosts Market • Market Trend: New Formulation Enhances Patient Access And Convenience • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Xgeva Market?

Xgeva (denosumab) refers to a monoclonal antibody used in the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and in the treatment of giant cell tumors of bone and osteoporosis in high-risk patients. It is utilized through subcutaneous injections administered by a healthcare professional. The main types of formulations in xgeva include 60 mg injection and 120 mg injection. Xgeva formulation with a dosage of 60 mg, typically administered as a single injection to address specific patient needs based on prescribed treatment regimens, focusing on conditions requiring lower dosages. The indications include bone metastases, giant cell tumor of bone (GCTB), and hypercalcemia of malignancy for end users such as hospitals, homecare, specialty clinics, and ambulatory surgical centers. The distribution channels include hospitals, retail pharmacies, and online pharmacies.

What Is The Xgeva Market Growth Forecast?

The growth in the forecast period can be attributed to increasing prevalence of metastatic cancers, rising demand for osteoporosis and bone health treatments, expansion of oncology supportive care services, growing adoption of biologic injectables, continued innovation in bone-targeted therapies. Major trends in the forecast period include increasing use of bone-targeted monoclonal antibodies, rising focus on skeletal-related event prevention, expansion of oncology supportive care therapies, growing adoption of injectable biologic treatments, enhanced emphasis on long-term bone health management.

Global Xgeva Market Segmentation

1) By Formulation: 60 Mg Injection, 120 Mg Injection 2) By Indication: Bone Metastases, Giant Cell Tumor of Bone (GCTB), Hypercalcemia of Malignancy 3) By End User: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Is The Driver Of The Xgeva Market?

The increasing prevalence of bone metastasis is propelling the growth of the xgeva market. Bone metastasis refers to the spread of cancer cells from their original site to the bones, often causing pain, fractures, and a range of other complications. The increase in prevalence of bone metastasis is due to the rising global incidence of cancers, particularly breast, prostate, and lung cancers, which are more likely to metastasize to the bones. As the prevalence of bone metastasis increases, the demand for effective treatments to manage bone-related complications also grows, positioning xgeva as a critical therapeutic option for preventing fractures and improving patient outcomes in individuals affected by metastatic bone disease. For instance in accrroding to the Cancer Research UK a UK-based cancer charity in 2038 to 2040, projections suggest that approximately 510 new cases of bone sarcoma may be diagnosed annually in the UK. Therefore, the increasing prevalence of bone metastasis is expected to drive the growth of the xgeva industry.

Key Players In The Global Xgeva Market

Major companies operating in the xgeva market are Amgen Inc.

Global Xgeva Market Trends and Insights

The key trend in the xgeva market is focusing on expanding their product offerings, enhancing formulations such as prefilled syringes, and improving patient access to treatment. A prefilled syringe refers to a single-dose, ready-to-use syringe preloaded with medication, designed to simplify administration, improve dosing accuracy, and enhance patient convenience. For instance, in March 2024, the Medicines and Healthcare Products Regulatory Agency, a UK-based government agency responsible for regulating medicines, approved a new high-concentration formulation of Amgen's Xgeva (denosumab) as a 120 mg solution for injection in a prefilled syringe. This approval, granted under the new International Recognition Procedure (IRP), enables UK patients to access a more convenient and streamlined treatment option. Furthermore, this move enhances patient experience by simplifying the administration process, reducing the volume of liquid injected, and lowering the risk of dosing errors.

What Are Latest Mergers And Acquisitions In The Xgeva Market?

In May 2024, Alvotech, a Luxembourg-based company specializing in the development and manufacture of biosimilar medicines, collaborated with Dr. Reddy’s Laboratories SA. to accelerate the commercialization of AVT03 (denosumab), a biosimilar candidate to Xgeva, by leveraging Dr. Reddy’s established presence in the U.S., Europe, and the UK, ensuring broader access to affordable treatment options for patients with conditions such as osteoporosis and bone-related complications from cancer. Dr. Reddy’s Laboratories SA is an India-based global pharmaceutical company involved in the development and manufacture of medicines.

Regional Insights

North America was the largest region in the xgeva market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Xgeva Market?

The xgeva market consists of sales of prefilled syringes and vials. Values in this market are ‘factory gate’ values, representing the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Xgeva Market Report 2026?

The xgeva market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the xgeva industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.